SAN JOSE, Calif., May 21, 2019 /PRNewswire/ -- Anixa Biosciences,
Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing
the body's immune system to fight cancer, today announced that it
will be presenting at the Sachs Associates 5th Annual
Immuno-Oncology BD&L and Investment Forum to be held
May 31, 2019 in Chicago.
Mike Catelani, COO and CFO of
Anixa, will provide an overview of the company, its most recent
accomplishments and upcoming milestones, with a focus on its
chimeric endocrine receptor t-cell (CER-T) treatment for ovarian
and other cancers. Management will also be available for
one-on-one meetings with investors who are registered to attend the
conference.
Details of Anixa's presentation are as follows:
Event:
|
5th Annual
Immuno-Oncology: BD&L and Investment Forum
|
Date:
|
Friday, May 31,
2019
|
Time:
|
12:10
p.m.
|
Location:
|
PR Track A -
Room Sinclair Ballroom
|
|
Waldorf Astoria
Chicago, Chicago, IL
|
The 5th Annual Immuno-Oncology BD&L and
Investment Forum is designed to bring together thought leaders from
cancer research institutes, patient advocacy groups, pharma and
biotech to facilitate partnering, funding and investment.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa is
developing a cancer immunotherapy program, which uses chimeric
endocrine receptor t-cell (CER-T) technology, a novel type of
CAR-T. Its CchekTM liquid biopsy technology is a
series of inexpensive non-invasive blood tests for early detection
of solid tumors based on the body's immune response to the presence
of a malignancy. This technology enables cancer detection in
its earliest stages in efforts to treat patients when the disease
is most curable. Anixa continually examines emerging
technologies in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Ingrid Mezo (Media)
imezo@tiberend.com
646-604-5150
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-sachs-associates-5th-annual-immuno-oncology-bdl-and-investment-forum-300853679.html
SOURCE Anixa Biosciences, Inc.